Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT06257355

PHASE1

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Corneal Scars

Sponsor: Claris Biotherapeutics, Inc.

View on ClinicalTrials.gov

Summary

This study will enroll subjects with recently formed corneal scars that resulted from a corneal insult presenting and diagnosed within the past approximately 30 days and not less than approximately 7 days. All subjects will be assigned to CSB-001 investigational treatment on Day 1. All subjects will dose with CSB-001 four times daily or three times daily starting on Day 1 and continue until Day 14. Subjects with a resolved scar at Day 7 will discontinue dosing and return to the clinic on Day 14. Subjects will return on Days 21, 28, 56, and Month 3 for safety and efficacy assessments.

Official title: A Two-Arm Open-Label Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Corneal Scars

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

Start Date

2024-02-05

Completion Date

2027-06-30

Last Updated

2026-04-07

Healthy Volunteers

Conditions

Corneal Scar

Interventions

BIOLOGICAL

CSB-001 Ophthalmic Solution 0.1%

CSB-001: human recombinant dHGF (5-amino acid deleted hepatocyte growth factor)

Inclusion Criteria: * Centrally or paracentrally located scar approximately ≤5 mm and ≥2 mm in the greatest diameter and with a portion of the scar within approximately 3.5 mm of the optical center of the cornea assessed at Screening and confirmed at Baseline, and subject reports ability to detect any effect of scar on any element of vision. * Eye with a recent corneal insult approximately ≤30 days and ≥7 days from the Screening Visit. * Corneal insult includes but is not limited to mechanical / chemical / thermal injury, bacterial keratitis, PRK, and contact lens related ulcer. * Eye with observed rate of epithelialization that in the investigator's opinion does not demonstrate clinical characteristics of a slow healing (persistent defect) cornea. * Subjects must have the ability and willingness to comply with study procedures. Exclusion Criteria: * Corneal scar that encompasses more than approximately 50% of the depth of the remaining stroma as guided by ASOCT image at the Screening Visit. * Maximum scar diameter greater than approximately 5 mm without prior approval by the Sponsor based on Screening Visit images. * No portion of the scar is within the approximate 3.5 mm of the optical center of the cornea based on Screening Visit images. * Any active ocular infection in the opinion of the investigator (bacterial, viral, fungal, or protozoal) at the Screening or Day 1 Visits. Subjects with an active bacterial infection at the Screening or Day 1 Visit in the opinion of the investigator may be rescheduled to reassess the status of the infection and continue in the study if infection is deemed not active. * Ocular surgery planned during the study treatment period. * Presence or history of any ocular or systemic disorder, condition or procedure that might hinder the efficacy of the study treatment or its evaluation, could possibly interfere with the interpretation of study results, or could be judged by the investigator to be incompatible with the study visit schedule or conduct. Note: Other inclusion/exclusion criteria apply.

Locations (7)

Loma Linda University Eye Institute

Loma Linda, California, United States

Midwest Cornea Associates, LLC

Carmel, Indiana, United States

Francis Price Jr, MD

Indianapolis, Indiana, United States

Minnesota Eye Consultants

Minnetonka, Minnesota, United States

Legacy Devers Eye Institute

Portland, Oregon, United States

Stuart A. Terry, MD PA

San Antonio, Texas, United States

Virginia Eye Consultants

Norfolk, Virginia, United States